High nuclear phosphorylated extracellular signal-regulated kinase expression associated with poor differentiation, larger tumor size, and advanced stage of breast cancer

Hsing Tao Kuo, Hui Ting Hsu, Chun Chao Chang, Ming Chung Jiang, Chung Min Yeh, Ko Hung Shen, Pei Chi Hsu, Cheng Jeng Tai

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Extracellular signal-regulated kinase (ERK1/2) is implicated in the malignant behavior of breast cancer cells. However, previous clinical-pathological studies have shown that expression of activated/phosphorylated ERK1/2 is not associated with enhanced proliferation and invasion of mammary carcinomas. ERK1/2 is expressed in the cytoplasm, and activated/phosphorylated ERK1/2 translocates to the nucleus. The aim of this study is to evaluate nuclear phosphorylated ERK1/2 as a biomarker for breast cancer prognosis. The clinical-pathological relation of cytoplasmic/nuclear phosphorylated ERK1/2 was analyzed in 105 surgically resected breast cancer specimens by immunohistochemistry with tissue microarray. The results showed that non-neoplastic breast tissue mainly showed faint phosphorylated ERK1/2 staining. No statistically significant association was found between the level of cytoplasmic phosphorylated ERK1/2 expression and the clinical features of the disease. High nuclear phosphorylated ERK1/2 expression was associated with high grade (poor differentiation, p = = 0.010), high T status (larger tumor size, p = 0.033), and an advanced stage (p = 0.018) of the disease. Thus, nuclear phosphorylated ERK1/2 is associated with enhanced pro-liferation and invasion of mammary carcinomas and may be a biomarker for breast cancer prognosis and the determination of therapeutic strategies.

Original languageEnglish
Pages (from-to)163-169
Number of pages7
JournalPolish Journal of Pathology
Volume64
Issue number3
DOIs
Publication statusPublished - 2013

Fingerprint

Extracellular Signal-Regulated MAP Kinases
Breast Neoplasms
Neoplasms
Biomarkers
Mitogen-Activated Protein Kinase 1
Cytoplasm
Breast
Immunohistochemistry
Staining and Labeling

Keywords

  • Breast cancer
  • ERK1/2
  • Nuclear
  • Phosphorylation
  • Prognosis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

High nuclear phosphorylated extracellular signal-regulated kinase expression associated with poor differentiation, larger tumor size, and advanced stage of breast cancer. / Kuo, Hsing Tao; Hsu, Hui Ting; Chang, Chun Chao; Jiang, Ming Chung; Yeh, Chung Min; Shen, Ko Hung; Hsu, Pei Chi; Tai, Cheng Jeng.

In: Polish Journal of Pathology, Vol. 64, No. 3, 2013, p. 163-169.

Research output: Contribution to journalArticle

@article{a64df0ab0972494bbb66fb20882fa09c,
title = "High nuclear phosphorylated extracellular signal-regulated kinase expression associated with poor differentiation, larger tumor size, and advanced stage of breast cancer",
abstract = "Extracellular signal-regulated kinase (ERK1/2) is implicated in the malignant behavior of breast cancer cells. However, previous clinical-pathological studies have shown that expression of activated/phosphorylated ERK1/2 is not associated with enhanced proliferation and invasion of mammary carcinomas. ERK1/2 is expressed in the cytoplasm, and activated/phosphorylated ERK1/2 translocates to the nucleus. The aim of this study is to evaluate nuclear phosphorylated ERK1/2 as a biomarker for breast cancer prognosis. The clinical-pathological relation of cytoplasmic/nuclear phosphorylated ERK1/2 was analyzed in 105 surgically resected breast cancer specimens by immunohistochemistry with tissue microarray. The results showed that non-neoplastic breast tissue mainly showed faint phosphorylated ERK1/2 staining. No statistically significant association was found between the level of cytoplasmic phosphorylated ERK1/2 expression and the clinical features of the disease. High nuclear phosphorylated ERK1/2 expression was associated with high grade (poor differentiation, p = = 0.010), high T status (larger tumor size, p = 0.033), and an advanced stage (p = 0.018) of the disease. Thus, nuclear phosphorylated ERK1/2 is associated with enhanced pro-liferation and invasion of mammary carcinomas and may be a biomarker for breast cancer prognosis and the determination of therapeutic strategies.",
keywords = "Breast cancer, ERK1/2, Nuclear, Phosphorylation, Prognosis",
author = "Kuo, {Hsing Tao} and Hsu, {Hui Ting} and Chang, {Chun Chao} and Jiang, {Ming Chung} and Yeh, {Chung Min} and Shen, {Ko Hung} and Hsu, {Pei Chi} and Tai, {Cheng Jeng}",
year = "2013",
doi = "10.5114/PJP.2013.38132",
language = "English",
volume = "64",
pages = "163--169",
journal = "Polish Journal of Pathology",
issn = "1233-9687",
publisher = "Versalius University Medical Publisher",
number = "3",

}

TY - JOUR

T1 - High nuclear phosphorylated extracellular signal-regulated kinase expression associated with poor differentiation, larger tumor size, and advanced stage of breast cancer

AU - Kuo, Hsing Tao

AU - Hsu, Hui Ting

AU - Chang, Chun Chao

AU - Jiang, Ming Chung

AU - Yeh, Chung Min

AU - Shen, Ko Hung

AU - Hsu, Pei Chi

AU - Tai, Cheng Jeng

PY - 2013

Y1 - 2013

N2 - Extracellular signal-regulated kinase (ERK1/2) is implicated in the malignant behavior of breast cancer cells. However, previous clinical-pathological studies have shown that expression of activated/phosphorylated ERK1/2 is not associated with enhanced proliferation and invasion of mammary carcinomas. ERK1/2 is expressed in the cytoplasm, and activated/phosphorylated ERK1/2 translocates to the nucleus. The aim of this study is to evaluate nuclear phosphorylated ERK1/2 as a biomarker for breast cancer prognosis. The clinical-pathological relation of cytoplasmic/nuclear phosphorylated ERK1/2 was analyzed in 105 surgically resected breast cancer specimens by immunohistochemistry with tissue microarray. The results showed that non-neoplastic breast tissue mainly showed faint phosphorylated ERK1/2 staining. No statistically significant association was found between the level of cytoplasmic phosphorylated ERK1/2 expression and the clinical features of the disease. High nuclear phosphorylated ERK1/2 expression was associated with high grade (poor differentiation, p = = 0.010), high T status (larger tumor size, p = 0.033), and an advanced stage (p = 0.018) of the disease. Thus, nuclear phosphorylated ERK1/2 is associated with enhanced pro-liferation and invasion of mammary carcinomas and may be a biomarker for breast cancer prognosis and the determination of therapeutic strategies.

AB - Extracellular signal-regulated kinase (ERK1/2) is implicated in the malignant behavior of breast cancer cells. However, previous clinical-pathological studies have shown that expression of activated/phosphorylated ERK1/2 is not associated with enhanced proliferation and invasion of mammary carcinomas. ERK1/2 is expressed in the cytoplasm, and activated/phosphorylated ERK1/2 translocates to the nucleus. The aim of this study is to evaluate nuclear phosphorylated ERK1/2 as a biomarker for breast cancer prognosis. The clinical-pathological relation of cytoplasmic/nuclear phosphorylated ERK1/2 was analyzed in 105 surgically resected breast cancer specimens by immunohistochemistry with tissue microarray. The results showed that non-neoplastic breast tissue mainly showed faint phosphorylated ERK1/2 staining. No statistically significant association was found between the level of cytoplasmic phosphorylated ERK1/2 expression and the clinical features of the disease. High nuclear phosphorylated ERK1/2 expression was associated with high grade (poor differentiation, p = = 0.010), high T status (larger tumor size, p = 0.033), and an advanced stage (p = 0.018) of the disease. Thus, nuclear phosphorylated ERK1/2 is associated with enhanced pro-liferation and invasion of mammary carcinomas and may be a biomarker for breast cancer prognosis and the determination of therapeutic strategies.

KW - Breast cancer

KW - ERK1/2

KW - Nuclear

KW - Phosphorylation

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=84885978121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885978121&partnerID=8YFLogxK

U2 - 10.5114/PJP.2013.38132

DO - 10.5114/PJP.2013.38132

M3 - Article

AN - SCOPUS:84885978121

VL - 64

SP - 163

EP - 169

JO - Polish Journal of Pathology

JF - Polish Journal of Pathology

SN - 1233-9687

IS - 3

ER -